| Line 1: |
Line 1: |
| − | Welcome! For assignments, please see the "Author" column below. If no name is present, volunteer to create content! | + | Welcome! |
| | | | |
| − | To volunteer, please contact the Associate Editor helping with your page of interest (email can be found on the <u>[[Leadership]]</u> page).
| |
| − | {| class="wikitable"
| |
| − | |+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content
| |
| − | |-
| |
| − | !'''Disease'''!!'''Page Type'''!!'''Author'''
| |
| − | !'''Date Assigned to Author'''
| |
| − | !'''Target Completion Date'''
| |
| − | !'''Author Content (Pending or Complete)'''
| |
| − | !'''Date Completed by Author'''!!'''Associate Editor'''
| |
| − | !'''Date of Last Editor Review'''
| |
| − | !'''Notes'''
| |
| − | |-
| |
| − | |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |Fabiola Quintero-Rivera (FQR)
| |
| − | |Date page was created
| |
| − | |
| |
| − | |-
| |
| − | | Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive||Disease
| |
| − | |Mark Evans (trainee)+Jack Reid (trainee)+Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |Date page was created
| |
| − | |
| |
| − | |-
| |
| − | | Chronic Neutrophilic Leukemia (CNL)||Disease
| |
| − | |Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |Date page was created
| |
| − | |
| |
| − | |-
| |
| − | | Polycythaemia Vera (PV)||Disease
| |
| − | |Gokce A. Toruner
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Primary Myelofibrosis (PMF)||Disease
| |
| − | |T. Niroshi Senaratne
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |8/4/2020 before submission
| |
| − | |
| |
| − | |-
| |
| − | | Essential Thrombocythaemia (ET)||Disease
| |
| − | |Rebecca Smith
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |8/1/21 FQR deleted "'''This page is under construction'''
| |
| − | |-
| |
| − | | Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease
| |
| − | |Chelsea D. Kramish (trainee), Daynna J.Wolff
| |
| − | |
| |
| − | |
| |
| − | |complete/pending faculty review
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease
| |
| − | |Thomas Lee
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Mastocytosis'''''||'''''Overview'''''||Shashi Shetty, Ph.D.
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | | ||FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Cutaneous Mastocytosis||Disease
| |
| − | |Thuy Phung + Shuo-Shawn Liu (trainee)
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |8/1/21 FQR deleted "'''This page is under construction'''
| |
| − | |-
| |
| − | | Systemic Mastocytosis||Disease
| |
| − | |Shashi Shetty
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mast Cell Sarcoma||Disease
| |
| − | |Thuy Phung +Jordan Lowery (trainee)
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''||Daynna J.Wolff
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement||Disease||Jay Alden (trainee) +Daynna J.Wolff
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement||Disease||Christopher Sullivan (trainee) + Daynna J.Wolff
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement||Disease||Yanna Ding
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease||Jessica Snider (trainee) + Daynna J.Wolff
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Myeloid/Lymphoid Neoplasms with ETV6-JAK2
| |
| − | |Disease
| |
| − | |Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |Myeloid/Lymphoid Neoplasms with BCR-JAK2
| |
| − | |Disease
| |
| − | |Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |'''''Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)'''''||'''''Overview'''''||Linsheng Zhang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Chronic Myelomonocytic Leukemia (CMML)||Disease||Linsheng Zhang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease||Linsheng Zhang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Juvenile Myelomonocytic Leukemia (JMML)||Disease||Sarah Rapisardo
| |
| − | |
| |
| − | |9/1/20
| |
| − | |PENDING reference formatting
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |Date page was created
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable||Disease||Ruth MacKinnon
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek?
| |
| − | |
| |
| − | |9/1/20
| |
| − | |pending
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia||Disease||Xiaoli Du(trainee) +Teresa Smolarek
| |
| − | |
| |
| − | |9/1/20
| |
| − | |PENDING
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome (MDS) with Excess Blasts||Disease||Xiaoli Du(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |9/1/20
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome (MDS) with Isolated del(5q)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome (MDS), Unclassifiable||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Refractory Cytopenia of Childhood||Disease||Xiaoli Du(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |9/1/20
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''||Daynna Wolff+Daniel Butler (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |Jennelle Hodge (JH)/ Malini Sathanoori (MS)
| |
| − | |04/26/2021 -MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | |'''''Myeloid Neoplasms with Germline Predisposition'''''||'''''Overview'''''||Ying Zou
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/01/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukaemia with Germline CEBPA Mutation||Disease||Daynna Wolff+Matthew Kilpatrick (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||JH / MS
| |
| − | |04/26/2021 -MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Neoplasms with Germline DDX41 Mutation||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/01/2021-MS
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Neoplasms with Germline RUNX1 Mutation||Disease||Malini Sathanoori
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |02/03/2021||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Neoplasms with Germline ANKRD26 Mutation||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/02/2021-MS
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Neoplasms with Germline ETV6 Mutation||Disease||Ying Zou
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/02/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Neoplasms with Germline GATA2 Mutation||Disease||Daynna Wolff+ Alexandria Avery (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |04/26/2021 -MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | |'''''Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities'''''||'''''Overview'''''||Daynna Wolff+ Dan Wang (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |JH / MS
| |
| − | |03/01/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease||Christine Bryke
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |04/26/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease||Christine Bryke
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/01/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Promyelocytic Leukemia (APL) with PML-RARA||Disease||Shashi Shetty
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/01/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease||Shashi Shetty
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/01/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease||Jennelle Hodge
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |02/24/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease||Gordana Raca
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |Need permission for figure? Update WHO?
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease||Jennelle Hodge
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease||Kay Weng Choy + Greg r
| |
| − | Conboy (Monash Health)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with Mutated NPM1||Disease||Xinjie Xu
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |Add WHO reference
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg Conboy (Monash Health)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with Mutated RUNX1||Disease||Daynna Wolff+Iris Martin (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Therapy-Related Myeloid Neoplasms||Disease||Shashi Shetty + Shawn A. Silver (resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |Check reference format
| |
| − | |-
| |
| − | |''Acute Myeloid Leukemia (AML), Not Otherwise Specified''||'''''Overview'''''||Anwar Iqbal
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with Minimal Differentiation||Disease||Fabiola Quintero-Rivera and Celeste Eno (fellow)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) without Maturation||Disease||Jennelle Hodge
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with Maturation||Disease||Jennelle Hodge
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myelomonocytic Leukemia||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Monoblastic and Monocytic Leukemia||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Pure Erythroid Leukemia||Disease||Ash Yenamandra
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Megakaryoblastic Leukemia (AMKL)||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Basophilic Leukemia||Disease||Ash Yenamandra
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Panmyelosis with Myelofibrosis||Disease||Ying Zou and Jialing Huang (MGP fellow)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Myeloid Sarcoma||Disease||Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Myeloid Proliferations Associated with Down Syndrome'''''||'''''Overview'''''||Patty Greipp
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |Need permission for figure?
| |
| − | |-
| |
| − | | Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome||Disease||Linda Cooley
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Leukemia Associated with Down Syndrome||Disease||Linda Cooley
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Blastic Plasmacytoid Dendritic Cell Neoplasm||Disease||Daynna Wolff+Hao Liu (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Acute Leukemias of Ambiguous Lineage'''''||'''''Overview'''''||Hui Chen/ Jennelle Hodge
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Undifferentiated Leukemia||Disease||Shashi Shetty + Amelia Nakanishi (resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |Check reference format
| |
| − | |-
| |
| − | | Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease||Tracy Tucker
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged||Disease||Tracy Tucker
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified||Disease||Shashi Shetty + Priyatharsini Nirmalanantham (resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified||Disease||Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types||Disease||Daynna Wolff+ Elicia Goodale (resident)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Leukemias of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease||Daynna Wolff+Madison Hannay or Elicia Goodale (residents)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Acute Myeloid Leukemia (AML) with Mutated FLT3
| |
| − | |Disease
| |
| − | |Kay Weng Choy + Greg Conboy (Monash Health)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |JH / MS
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |Acute Myeloid Leukemia (AML) with NUP214-ABL1
| |
| − | |Disease
| |
| − | |Daynna Wolff+Jessica Snider (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |JH / MS
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6
| |
| − | |Disease
| |
| − | |Daynna Wolff+ Paige Woodham (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |JH / MS
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||Yassmine Akkari (YA)
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||Marilena Melas + Yassmine Akkari
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease||Afia Hasnain + Yassmine Akkari
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy||Disease||Ashwini Yenamandra +
| |
| | | | |
| − | Lisa Smith + Yassmine Akkari
| + | We are creating content for all diseases with genetic findings in the current WHO Classification of Tumours books. Please join the effort! |
| − | |
| + | |
| − | |
| + | |
| − | |Complete
| + | To volunteer: |
| − | |
| + | |
| − | |YA
| + | #Select a link in the table to your book(s) of interest to view specific authorship opportunities. Additional books are in the process of being added. |
| − | |
| + | #'''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]''' with your disease page of interest. You will be connected with an Associate Editor to help guide you through the process. |
| − | |
| + | #Complete the brief '''[https://mms.cancergenomics.org/members/form.php?orgcode=CGC&fid=3830649 <u>Volunteer Form</u>]''' to receive your log-in credentials. Information on [[Description of CCGA Roles|<u>Authorship and Other Roles</u>]] with the CCGA is available. |
| − | |-
| + | |
| − | | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease||Binu Porath + Linda Cooley
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease||Binu Porath + Linda Cooley
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease||Holli Drendel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease||Holli Drendel
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
| |
| − | |Disease
| |
| − | |Diana Rush
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |YA
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
| |
| − | |Disease
| |
| − | |Celeste Eno
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |YA
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
| |
| − | |Disease
| |
| − | |Marilena Melas
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |YA
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
| |
| − | |Disease
| |
| − | |Chenkai Ma
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |YA
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
| |
| − | |Disease
| |
| − | |Celeste Eno
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |YA
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
| |
| − | |Disease
| |
| − | |Alaa Koleilat
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |YA
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||YA
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||Snehal Patel (SP)
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Jamie Nagy
| |
| − | |10/25/21
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Monoclonal B-cell Lymphocytosis||Disease||Jamie Nagy
| |
| − | |10/25/21
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |B-cell Prolymphocytic Leukemia||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Hairy Cell Leukemia||Disease||Snehal Patel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Splenic Diffuse Red Pulp Small B-cell Lymphoma||Disease||Snehal Patel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Hairy Cell Leukemia Variant||Disease||Snehal Patel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Lymphoplasmacytic Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Waldenstrom Macroglobulinemia||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Heavy Chain Diseases'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mu Heavy Chain Disease||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Gamma Heavy Chain Disease||Disease||Manisha Sutariya
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |5/26/2021||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Alpha Heavy Chain Disease||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Non-IgM Monoclonal Gammopathy of Undetermined Significance||Disease||Zhenya Tang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Plasmacytoma||Disease||Zhenya Tang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||Chen Yang, MD, PhD
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Primary Amyloidosis||Disease||Heather E. Williams, PhD
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Light Chain and Heavy Chain Deposition Disease||Disease||Chen Yang, MD, PhD
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
| |
| − | |8/31/2021
| |
| − | |9/15/2021
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | POEMS Syndrome||Disease||Sohini Anand, MBBS, and Tharanga Niroshini Senaratne, PhD
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | TEMPI Syndrome||Disease||Sohini Anand, MBBS
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
| |
| − | |3/9/21
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |5/28/2021||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |11/11/2020
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Follicular Lymphoma||Disease||Ruthann Pfau
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Testicular Follicular Lymphoma||Disease||Ruthann Pfau
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | In Situ Follicular Neoplasia||Disease||Ruthann Pfau
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |8/16/2020
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid
| |
| − | |
| |
| − | |9/30/20
| |
| − | |Complete
| |
| − | |5/26/2021||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Mantle Cell Lymphoma||Disease||Mahsa Khanlari
| |
| − | |
| |
| − | |8/15/20
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Leukemic Non-Nodal Mantle Cell Lymphoma||Disease||Mahsa Khanlari, MD
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | In Situ Mantle Cell Neoplasia||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |Greg Corboy (GC)
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||Laveniya Satgunaseelan
| |
| − | |26/10/2021
| |
| − | |26/1/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |EBV-Positive Mucocutaneous Ulcer||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Fibrin-Associated Diffuse Large B-cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Lymphomatoid Granulomatosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Intravascular Large B-cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ALK-Positive Large B-cell Lymphoma||Disease||Nakasaki, Manando(trainee)+ Fabiola Quintero-Rivera
| |
| − | |6/1/21
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Primary Effusion Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Multicentric Castleman Disease||Disease||Sudha Arumugam
| |
| − | |10/26/2021
| |
| − | |1/26/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | | HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sudha Arumugam
| |
| − | |10/26/2021
| |
| − | |1/26/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | | HHV8-Positive Germinotropic Lymphoproliferative Disorder||Disease||Sudha Arumugam
| |
| − | |10/26/2021
| |
| − | |1/26/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
| |
| − | |3/11/21
| |
| − | |06/28/2021
| |
| − | |Complete
| |
| − | |28/06/2021||GC
| |
| − | |28/06/2021
| |
| − | |
| |
| − | |-
| |
| − | |Burkitt-Like Lymphoma with 11q Aberration||Disease||Lauren Shealy (trainee), Daynna Wolff
| |
| − | |10/13/21
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||Kate Berry, Greg Corboy
| |
| − | |30/05/21
| |
| − | |30/08/21
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Aiko Otsubo, Holli Drendel
| |
| − | |7/30/21
| |
| − | |10/30/21
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||Snehal Patel (SP)
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |T-cell Prolymphocytic Leukemia||Disease||Michelle Don
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Severe Mosquito Bite Allergy||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Extranodal NK/T-cell Lymphoma, Nasal Type||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |1/21/2021
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Monomorphic Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Hepatosplenic T-cell Lymphoma||Disease||Michelle Don
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |1/21/2021
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Mycosis Fungoides||Disease||Daynna Wolff, Jane Scribner (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Lymphomatoid Papulosis||Disease||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||Peining Li, PhD
| |
| − | |
| |
| − | | | |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Angioimmunoblastic T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Follicular T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease||Hans Hamnvåg
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SP
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Hodgkin Lymphomas'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||Greg Corboy (GC)
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Nodular Sclerosis Classic Hodgkin Lymphoma||Disease||Xiaolin (Lynn) Hu
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | | Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | | Mixed Cellularity Classic Hodgkin Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | | Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Lymphomas Associated with HIV Infection||Disease||Patricia V. Hernandez, M.D.
| |
| − | |11/2/21
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Non-Destructive Post-Transplant Lymphoproliferative Disorders||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Polymorphic Post-Transplant Lymphoproliferative Disorders||Disease||Anna Shestakova (trainee)''+,''
| |
| | | | |
| − | Fabiola Quintero-Rivera
| + | {| class="wikitable" |
| − | |
| + | |+BOOKS WITH CONTENT IN PROGRESS |
| − | |
| + | !Book Name |
| − | |PENDING
| + | !Book Edition |
| − | |
| + | !Book Acronym |
| − | |GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''''' Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Monomorphic B-cell PTLD||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Monomorphic T/NK-cell PTLD||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Histiocytic Sarcoma||Disease||Marie-France Gagnon, MD, Mayo Clinic (LGG fellow trainee), Xinjie Xu, PhD FACMG, Mayo Clinic
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |10/01/2021
| |
| − | |GC
| |
| − | |10/01/2021
| |
| − | |Xinjie Xu
| |
| − | |-
| |
| − | |'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Langerhans Cell Histiocytosis||Disease||Prashant Deshpande
| |
| − | |10/26/2021
| |
| − | |1/26/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | | Langerhans Cell Sarcoma||Disease||Prashant Deshpande
| |
| − | |10/26/2021
| |
| − | |1/26/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Indeterminate Dendritic Cell Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Interdigitating Dendritic Cell Sarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Follicular Dendritic Cell Sarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Fibroblastic Reticular Cell Tumor||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Disseminated Juvenile Xanthogranuloma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Erdheim-Chester Disease||Disease||Prashant Deshpande
| |
| − | |10/26/2021
| |
| − | |1/26/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | | | |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| | |- | | |- |
| − | | || || | + | |[[HAEM5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues]] |
| − | |
| + | |5th |
| − | |
| + | |HAEM5 |
| − | |
| |
| − | | ||
| |
| − | | | |
| − | | | |
| | |- | | |- |
| − | | || || | + | |[[CNS5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of the Central Nervous System]] |
| − | |
| + | |5th |
| − | |
| + | |CNS5 |
| − | |
| |
| − | | ||
| |
| − | | | |
| − | | | |
| | |- | | |- |
| − | | || || | + | |[[GTS5:Volunteer Assignments and Opportunities|WHO Classification of Genetic Tumour Syndromes]] |
| − | |
| + | |5th |
| − | |
| + | |GTS5 |
| − | |
| |
| − | | ||
| |
| − | | | |
| − | | | |
| | |- | | |- |
| − | | || || | + | |[[BRST5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of the Breast]] |
| − | |
| + | |5th |
| − | |
| + | |BRST5 |
| − | |
| |
| − | | ||
| |
| − | | | |
| − | | | |
| | |- | | |- |
| − | | || || | + | |[[STBT5:Volunteer Assignments and Opportunities|WHO Classification of Soft Tissue and Bone Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |STBT5 |
| − | |
| |
| − | | ||
| |
| − | | | |
| − | | | |
| | |- | | |- |
| − | | || || | + | |[[DIG5:Volunteer Assignments and Opportunities|WHO Classification of Digestive System Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |DIG5 |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | | | |
| − | | | |
| | |} | | |} |
| | + | |
| | | | |
| | {| class="wikitable" | | {| class="wikitable" |
| − | |+WHO Classification of Tumours of the Central Nervous System Content | + | |+BOOKS COMING SOON |
| − | |-
| + | !Book Name |
| − | !'''Disease'''!!'''Page Type'''!!'''Author'''
| + | !Book Edition |
| − | !'''Date Assigned to Author'''
| + | !Book Acronym |
| − | !'''Target Completion Date''' | |
| − | !'''Author Content (Pending or Complete)''' | |
| − | !'''Date Completed by Author'''!!'''Associate Editor''' | |
| − | !'''Date of Last Editor Review'''
| |
| − | !'''Notes'''
| |
| − | |-
| |
| − | |'''''Medulloblastoma, WNT-activated'''''||'''''Disease'''''||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
| |
| − | |9/20/21
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |}
| |
| − | | |
| − | {| class="wikitable sortable"
| |
| − | |+Gene-Specific Pages
| |
| − | !'''Gene'''
| |
| − | !'''Author'''
| |
| − | !'''Date Assigned to Author'''
| |
| − | !'''Target Completion Date'''
| |
| − | !'''Author Content (Pending or Complete)'''
| |
| − | !'''Date Completed by Author'''
| |
| − | !'''Associate Editor'''
| |
| − | !'''Date of Last Editor Review'''
| |
| − | !'''Notes'''
| |
| − | |-
| |
| − | |BCR
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |8/10/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ABL1
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |4/16/19
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RUNX1
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |6/9/19
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RUNX1T1
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |5/23/19
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MYH11
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |8/6/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |FLT3
| |
| − | |Kay Weng Choy
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |NPM1
| |
| − | |Kay Weng Choy
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |TP53
| |
| − | |Kay Weng Choy
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |DNMT3A
| |
| − | |Kay Weng Choy
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CEBPA
| |
| − | |Gordana
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |IDH1
| |
| − | |Paul De Fazio
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |IDH2
| |
| − | |Paul De Fazio
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |PML
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |12/5/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RARA
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |8/3/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ETV6
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |6/9/19
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |KIT
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |10/1/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CBFB
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |8/2/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |GATA2
| |
| − | |Kay Weng Choy
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |PTEN
| |
| − | |Beth Pitel
| |
| − | |
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MLTT3
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MECOM
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |FGFR1(FLT2)
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |KMT2A
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |DEK
| |
| − | |Wahab A. Khan
| |
| − | |
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |NUP214
| |
| − | |Wahab A. Khan
| |
| − | |
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RBM15
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MKL1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |DDX41
| |
| − | |Ying Zou
| |
| − | |8/7/20
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ANKRD26
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CUX1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |TET2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |EZH2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |FOXP1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MYC
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |JAK2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |WT1
| |
| − | |DONE
| |
| − | |
| |
| − | |
| |
| − | |DONE
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CBL
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |NF1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |SUZ12
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ERG
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |EST2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RPS14
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RB1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MPL
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CHGA
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CDH1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |SRSF2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |DNMT1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |PRDX2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ASXL1
| |
| − | |DONE
| |
| − | |
| |
| − | |
| |
| − | |DONE
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| | |- | | |- |
| − | |MN1 | + | |[[EYE5:Volunteer Assignments and Opportunities|WHO Classification of Eye and Orbit Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |EYE5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |SF3A1 | + | |[[SKIN5:Volunteer Assignments and Opportunities|WHO Classification of Skin Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |SKIN5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |EP300 | + | |[[HAN5:Volunteer Assignments and Opportunities|WHO Classification of Head and Neck Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |HAN5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |JARID2 | + | |[[ENDO5:Volunteer Assignments and Opportunities|WHO Classification of Endocrine and Neuroendocrine Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |ENDO5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |BRCA1 | + | |[[MALE5:Volunteer Assignments and Opportunities|WHO Classification of Urinary and Male Genital Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |MALE5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |BRCA2 | + | |[[PEDS5:Volunteer Assignments and Opportunities|WHO Classification of Paediatric Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |PEDS5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | | | + | |[[THOR5:Volunteer Assignments and Opportunities|WHO Classification of Thoracic Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |THOR5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | | | + | |[[FEMA5:Volunteer Assignments and Opportunities|WHO Classification of Female Genital Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |FEMA5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |} | | |} |